Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 8Sunitinib 7enfortumab vedotin 6Abiraterone Acetate 6enzalutamide 5Nivolumab 5Gemcitabine 5Cisplatin 5Carboplatin 4avelumab 3Prednisone 3Ipilimumab 3Docetaxel 3Androgen Antagonists 3sacituzumab govitecan 2olaparib 2niraparib 2erdafitinib 2entrectinib 2durvalumab 2darolutamide 2cabozantinib 2belzutifan 2apalutamide 2Pluvicto 2Mitomycin 2Leuprolide 2Everolimus 2Axitinib 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Saline Solution × Genitourinary × Clear all
NCT03142334 2026-03-10

KEYNOTE-564

Merck Sharp & Dohme LLC

Phase 3 Completed
994 enrolled 10 charts 1 FDA
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡